
FIG. 1. Growth of RAds in HEK 293A cells.

10

10<sup>7</sup> — A—RAdEa — D— RAdEs — D— R

FIG. 2. Synthesis of JEV proteins in HEK 293A cells infected with RAds.



PCT/IN2004/000432

(

25

FIG. 3. Immunofluorescent staining of virus-infected cells.




FIG. 4. Antibody response in mice.




FIG. 5. Isotype analysis of anti-JEV antibody produced by immunized mice.




FIG. 6. JEV neutralizing antibody response in mice.




FIG. 7. Cytokine production by splenocytes from immunized mice.

10 RAdEs IM 1x10<sup>8</sup> PFU RAdEs Oral 1x10<sup>8</sup> PFU RAdEa IM 7.5x10<sup>5</sup> PFU RAdEa Oral 3x10<sup>6</sup> PFU Vaccine 100 µl 2000 15 1750 1500 1250 20 1000 750 25 500 250° 1234 1234 0. 1234 1234 1234 1234 30 1234 140 120-35 100-IL-5 (pg/ml) 80 60 40 40 20 45 1234 1234 0 1234 1234 1234 1234 1234 1234 1234

50

55


FIG. 8. CTL activity in immunized mice

10

15

20

25



Effector: Target ratio

FIG. 9. Mice survival after challenge.

30

